Saturday, June 13, 2026

Intelligence · Clinical Development

Pipeline search results

Programs matching “ischemic stroke” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.

Matching programs 60
Total indexed 20,548
Sponsors 1,769

Quick answer

Showing 60 pipeline programs matching "ischemic stroke" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.

Refine search

60 results for “ischemic stroke” Back to intelligence hub

Search results

Page 2 of 3
  1. 16-739

    Disc Medicine

    Perinatal Arterial Ischemic Stroke (PAIS)

    phase 2 small molecule active

    1 trial
  2. Bu-Yang-Huan-Wu Tang

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Ischemic Stroke

    phase 2 small molecule active

    1 trial
  3. CARBOCAINE 20 mg/ml, solution injectable

    Pari Pharma GmbH

    Ischemic stroke

    phase 2 small molecule active

    1 trial
  4. GEN-100

    Lacuna Pharma Pty Ltd

    Acute Ischemic Stroke

    phase 2 small molecule active

    1 trial
  5. Human Adipose-Derived Stem Cell Exosomes

    The First People's Hospital of Lianyungang

    Acute Ischemic Stroke

    phase 2 mab active

    1 trial
  6. PURSUIT

    AstraZeneca AB

    Dyslipidemia Dyslipidemias are alterations to the plasma lipid profile associated often with clinical condition. A common form of dyslipidemia is Hypercholesterolemia due to high level of LDL-cholesterol, which is a major risk factor for Cardiovascular Disease (CVD), such as Ischemic Heart Disease and Ischemic Stroke. CVD is a leading cause of global mortality and a contributor to disability.

    phase 2 small molecule active

    1 trial
  7. Recombinant human tissue kallikrein

    DiaMedica Therapeutics

    Acute Ischemic Stroke

    phase 2 small molecule completed

    1 trial
  8. SODIUM CHLORIDE SOLUTION 0.9%

    Lacuna Pharma Pty Ltd

    Acute Ischemic Stroke

    phase 2 small molecule active

    1 trial
  9. TAK-755

    Takeda

    Acute Ischemic Stroke

    phase 2 mab active

    1 trial
  10. Tenecteplase

    Neuroscience Trials Australia

    Ischemic Stroke

    phase 2 small molecule completed

    1 trial
  11. 22375

    Bayer AG

    Prevention of ischemic stroke in patients after an acute non-cardioembolic ischemic stroke or high-risk transient ischemic attack in combination with antiplatelet therapy

    phase 1 other active

    1 trial
  12. 22665

    Bayer AG

    Prevention of ischemic stroke in patients post acute non-cardioembolic ischemic stroke or high-risk transient ischemic attack

    phase 1 other active

    1 trial
  13. 22806

    Bayer AG

    atrial fibrillation, transient ischemic attack (TIA), ischemic stroke

    phase 1 other active

    1 trial
  14. Intercerebral implantation of allogenic CD34+ stem cell

    Hospital Authority, Hong Kong

    Ischemic Stroke

    phase 1 other active

    1 trial
  15. hUCB

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Acute Ischemic Stroke

    phase 1 other completed

    1 trial
  16. Edaravone dexborneol

    The First People's Hospital of Lianyungang

    Acute Ischemic Stroke

    approved small molecule active

    1 trial
  17. IIBSP-HOP-2021-01

    The George Institute

    Acute Ischemic Stroke

    approved small molecule active

    1 trial
  18. Intravenous thrombolysis + edaravone

    The First People's Hospital of Lianyungang

    Ischemic Stroke

    approved small molecule active

    1 trial
  19. Minocycline

    The First People's Hospital of Lianyungang

    Ischemic Stroke, Acute

    approved small molecule active

    2 trials
  20. Qizhitongluo Capsule

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Ischemic Stroke

    approved small molecule completed

    1 trial
  21. Rucacuzumab plus standard therapy

    The First People's Hospital of Lianyungang

    Acute Ischemic Stroke AIS

    approved small molecule active

    1 trial
  22. Xingnaojing injection

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Acute Ischemic Stroke

    approved small molecule active

    1 trial
  23. Xingnaojing injection

    The First People's Hospital of Lianyungang

    Ischemic Stroke, Acute

    approved small molecule active

    1 trial
  24. Xingnaojing injection

    Universal Integrated

    Acute Ischemic Stroke

    approved small molecule active

    1 trial

Frequently asked questions

What is the Clinical Development Intelligence Platform?

It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.

How does this compare to Evaluate Pharma or Citeline?

Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.

Where does pipeline data come from?

Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.

Can I follow a company or program for updates?

Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.